Subtype
Prostate Neuroendocrine Neoplasm
CI-CAN-00001444Explore in graph →
Non-malignant8 active trials
Loading cancer entity…
Subtype
CI-CAN-00001444Explore in graph →
Clinical trials
12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT05691465 | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06062745 |
Data updated 16 hours agoSource updated Sep 29, 2026source: clinicaltrials
| recruiting |
| Phase 1 |
| 30 |
| Brigham and Women's HospitalOTHER |
| 1 |
| Nov 5, 2025 |
| clinicaltrials |